The Price of Power: Friday's Top 10 Lobbying Scandals

## The Corrosive Hand of Influence: When Corporations Buy Policy

In the shadowed halls of power, where policy is forged and regulations are written, a potent force often operates beyond public scrutiny: corporate lobbying. Ostensibly a legitimate means for businesses to voice their concerns and contribute to policy discussions, this practice frequently morphs into a vehicle for undue influence, distorting democratic processes and prioritizing private profit over public good. The line between advocacy and corruption can blur, leading to environments where campaign contributions, revolving-door appointments, and direct financial incentives shape legislation to benefit specific corporate interests, often at the expense of environmental protection, consumer safety, labor rights, and fair competition.

This week, we pull back the curtain on ten stark examples of corporate malfeasance in the realm of lobbying and political corruption. These aren't just stories of ambition; they are documented instances where companies have actively sought to manipulate the political system, sometimes through legal but ethically questionable means, and other times through outright illicit activities. The repercussions range from crippling financial penalties and tarnished reputations to devastating public health crises and environmental catastrophes, underscoring the profound and often silent impact of corporate influence on our daily lives.

---

### The Friday Top 10: Worst Corporate Offenders in Lobbying and Political Corruption

#### **10. Purdue Pharma**

**Incident(s):** For decades, **Purdue Pharma** aggressively marketed its opioid painkiller OxyContin, downplaying its addictive nature, even as the opioid crisis spiraled. Investigations revealed extensive lobbying efforts and financial incentives provided to doctors to promote the drug. The company used a network of sales representatives to push high-dose prescriptions, often targeting doctors who were high prescribers of opioids. Their actions directly contributed to the widespread addiction epidemic in the U.S. and beyond.

**Year(s):** 1996 - present (with major revelations and legal actions peaking in the 2000s and 2010s).

**Concrete Impact:** In 2007, Purdue Pharma and three executives pleaded guilty to federal criminal charges of misbranding OxyContin, paying **$634.5 million in fines**. In 2020, the company pleaded guilty to three federal criminal charges, including conspiracy to defraud the United States and violating anti-kickback laws, agreeing to a **$8.3 billion criminal and civil settlement**, though much of this was never paid due to bankruptcy proceedings. The opioid crisis has claimed hundreds of thousands of lives and cost the U.S. economy trillions of dollars. The Sackler family, owners of Purdue, faced numerous lawsuits and settlements, with ongoing disputes over their personal liability and attempts to shield assets.

**Why it ranks here:** While the scale of the opioid crisis is immense, and Purdue's role undeniable, its lobbying efforts, though aggressive, often operated within the legal (though ethically dubious) framework of pharmaceutical promotion and influence, rather than overt bribery or direct political corruption of public officials, which characterizes higher-ranked entries.

**Sources:**
* [Purdue Pharma Pleads Guilty to Federal Charges, Admits Misleading Public About OxyContin](https://www.justice.gov/opa/pr/purdue-pharma-pleads-guilty-federal-charges-admits-misleading-public-about-oxycontin) - U.S. Department of Justice, 2020.
* [OxyContin Maker, Executives Enter Pleas in Federal Court](https://www.washingtonpost.com/wp-dyn/content/article/2007/05/10/AR2007051000705.html) - The Washington Post, 2007.
* [The Sackler Family and Purdue Pharma: A Timeline of the Opioid Crisis](https://www.nytimes.com/2019/09/07/health/purdue-pharma-sacklers-opioids.html) - The New York Times, 2019.

#### **9. Mallinckrodt Pharmaceuticals**

**Incident(s):** **Mallinckrodt Pharmaceuticals** engaged in aggressive lobbying and pricing strategies, particularly concerning its drug Acthar Gel. The company acquired the drug in 2014 and dramatically increased its price, from approximately $1,600 per vial in 2001 to over $34,000 by 2015. Investigations revealed that Mallinckrodt underpaid Medicaid rebates for years by misclassifying the drug, costing taxpayers hundreds of millions.

**Year(s):** 2013-2022.

**Concrete Impact:** In 2020, the company agreed to pay **$260 million** to settle allegations that it knowingly underpaid Medicaid rebates for Acthar Gel. This settlement was part of a larger pattern of alleged misconduct, including price gouging. Additionally, Mallinckrodt filed for bankruptcy in 2020, largely due to its liabilities stemming from the opioid crisis, where it was a significant manufacturer of generic opioids. The company faced numerous lawsuits regarding its marketing and sales practices for opioids, contributing to the public health crisis.

**Why it ranks here:** Mallinckrodt